Novonesis, operating under Novozymes A/S, effectively priced and concluded the sale of EUR 1.7 billion senior unsecured notes, known as the "Notes," on March 12, 2026. This transaction was conducted under the fresh EUR 4 billion Euro Medium Term Note (EMTN) Programme, which was initiated on March 10, 2026.